摘要Precise risk stratification is crucial for selecting the optimal risk-adapted treatment for newly diagnosed multiple mye-loma(NDMM)patients.Various prognostic factors and stag-ing systems have been developed to predict NDMM patient outcomes.The Durie-Salmon(D-S)staging system reflects tumor burden and clinical progression staging with prognos-tic value.However,the discrepancy in outcomes between D-S stage II and III patients is not significant and the efficacy in prognostic prediction in the era of new drugs is somewhat unsatisfactory1.
作者单位Department of Hematology and Cell Therapy,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou 310016,China;Department of Nephrology,Affiliated Hospital of Jiaxing University(The First Hospital of Jiaxing),Jiaxing 314001,China[1]Department of Hematology and Cell Therapy,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou 310016,China[2]
换一批
